查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1464762

药物製剂市场：按剂型、技术、治疗领域和最终用户 - 2024-2030 年全球预测

Drug Formulation Market by Dosage Form, Technology, Therapeutic Area, End User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年药品製剂市场规模为2.42兆美元，预计2024年将达2.55兆美元，2030年将达3.56兆美元，复合年增长率为5.70%。

药物製剂是指将活性药物成分（API）与其他物质结合以形成对患者安全、有效且方便的最终药物产品的过程。这个复杂的技术过程涉及选择适当的赋形剂，以确保 API 在人体内的稳定性、生物利用度和最佳性能。慢性病的流行、药物传输技术的进步以及个人化医疗的进步正在增加对更多药物製剂的需求。儘管潜力巨大，但药物製剂仍面临着开发成本高、监管障碍以及创建在口味和给药方面稳定且患者可接受的製剂的复杂性等挑战。解决这些限制需要持续投资于研发、采用创新技术并确保监管策略的适应性和效率。奈米技术、缓释性和生物分解性聚合物等新型药物传递系统的探索可望进一步提高药物疗效和患者依从性，从而有可能改变药物医学的模式。

主要市场统计
基准年[2023] 2.42兆美元
预测年份 [2024] 2.55兆美元
预测年份 [2030] 3.56兆美元
复合年增长率（%） 5.70%

剂型：慢性治疗中口服製剂的便利性与有效性

吸入製剂设计为直接给药至呼吸道。它主要用于治疗影响肺部的疾病，例如气喘和慢性阻塞性肺病（COPD）。製剂起效快，全身副作用少。对于需要立即缓解或治疗的肺部疾病，此方法是首选。口服製剂如锭剂、胶囊和液体是最常见的给药型态。这些製剂被设计为透过胃肠道（GI）被全身吸收，并且由于其易于给药且患者依从性高而被广泛优选用于慢性疾病。肠胃外製剂绕过胃肠道，主要经由静脉、肌肉或皮下途径给药。肠胃外製剂对于需要快速吸收的治疗或胃肠道吸收不良的药物的给药至关重要。这对于需要精确控制药物生物有效性的急救药物、生技药品和治疗至关重要。外用产品包括涂布在皮肤表面的霜剂、软膏、凝胶和贴片。它们主要用于局部治疗，具有最大限度减少全身暴露的优点。透过局部给药来治疗皮肤病和疼痛的理想选择。

最终用户：药厂加大药物研发投资

学术研究机构主要致力于开发创新製剂和药物传递系统。此外，人们经常寻找具有​​潜在治疗作用的新化合物。合约药物开发和受託製造厂商（CDMO）在药物製剂领域发挥着至关重要的作用，提供从药物开发到製造的广泛服务。 CDMO 迎合注重弹性、扩充性和上市速度的製药公司，旨在将这些方面外包以专注于核心竞争力。医院和诊所是透过药物管理致力于病患照护的主要最终使用者。他们喜欢安全、有效且能提高病患依从性的药物。该行业对能够简化给药方案和改善治疗效果的製剂特别感兴趣。製药公司是药物製剂产业的核心参与者，从事药物的发现、开发、生产和销售。

区域洞察

在美洲，尤其是美国，由于大型製药公司的存在以及以 FDA 为中心的完善的法律规范，非常重视创新的药物製剂技术。因此，人们对研发（R&D）进行了积极投资，重点关註生技药品和缓释性等复杂製剂。此外，先进的製造设备增强了美洲的生产能力，使新配方能够快速扩展。由于医疗保健成本不断上升、对学名药的需求不断增长以及法规结构不断完善，亚太地区正在迅速成为药品製剂市场的主要参与者。印度和中国等国家利用其具有成本效益的製造和庞大的科学人才库，在学名药生产方面处于领先地位。欧洲、中东和非洲地区是一个成熟的市场，非常注重高品质的药物配方和严格的监管标准，特别是在欧盟 (EU) 国家。私人公司是先进给药系统和个人化医疗领域的领导者，并得到强大的医疗保健系统以及政府和私人对药物研发的大量投资的支持。

FPNV定位矩阵

FPNV定位矩阵对于评估药品製剂市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对药物製剂市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告对以下几个方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4. 竞争评估和情报：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况和製造能力进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1. 药品製剂市场的市场规模与预测为何？

2.在药物製剂市场的预测期间内，有哪些产品、细分市场、应用和领域需要考虑投资？

3.药品製剂市场的技术趋势和法规结构是什么？

4.药品製剂市场主要厂商的市场占有率为何？

5. 进入药品製剂市场的合适型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 慢性病的流行和有效治疗的需要
      • 政府鼓励药物开发和发现的努力
      • 个人化医疗和治疗方法的兴起
    • 抑制因素
      • 因不利事件而召回
    • 机会
      • 药物传输和给药技术的进步
      • 学名药开发CDMO投资
    • 任务
      • 药物配方的复杂开发与加工
  • 市场区隔分析
    • 剂型：口服製剂在慢性治疗的便利性与有效性
    • 最终用户：药厂加大药物研发投资
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章以剂型分類的药物製剂市场

  • 吸入製剂
  • 口服製剂
  • 肠外製剂
  • 局部製剂

第七章药物製剂市场：依技术分类

  • 速效製剂
  • 微脂体体製剂
  • 微球製剂
  • 改良释放製剂
  • 奈米配方
  • 自乳化给药系统
  • 固体分散体製剂

第八章依治疗领域分類的药物製剂市场

  • 心血管
  • 中枢神经系统
  • 皮肤科
  • 内分泌学
  • 胃
  • 免疫学
  • 感染疾病
  • 肿瘤学
  • 眼科
  • 疼痛管理
  • 呼吸系统

第九章药物製剂市场：依最终使用者分类

  • 学术/研究机构
  • 合约开发和製造组织
  • 医院/诊所
  • 製药公司

第十章美洲药物製剂市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太药物製剂市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲药品製剂市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Glenmark 在印度推出针对 2 型糖尿病患者的三重药物配方
    • Neurocrine Biosciences 宣布美国FDA 已接受其 INGREZZA（Valbenazine）口服颗粒喷剂新药申请
    • 默克和 XtalPi 合作利用人工智慧技术优化药物处方
  • 战略分析和建议

第14章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-351BAD50373D

[193 Pages Report] The Drug Formulation Market size was estimated at USD 2.42 trillion in 2023 and expected to reach USD 2.55 trillion in 2024, at a CAGR 5.70% to reach USD 3.56 trillion by 2030.

Drug formulation refers to the process through which active pharmaceutical ingredients (APIs) are combined with other substances to create a final medicinal product that is safe, effective, and convenient for patients to use. This technical and intricate process involves choosing suitable excipients to ensure the stability, bioavailability, and optimal performance of the API in the human body. The prevalence of chronic diseases, advancements in drug delivery technologies, and the escalation of personalized medicine have been elevating the need for more drug formulations. Despite the immense potential, drug formulation faces challenges such as the high cost of development, regulatory hurdles, and the complexity of creating formulations that are both stable and acceptable to patients in terms of taste and administration method. Addressing these restraints requires continuous investment in R&D, adopting innovative technologies, and ensuring regulatory strategies are adaptable and efficient. The exploration of novel drug delivery systems such as nanotechnology, sustained-release formulations, and biodegradable polymers is expected to further enhance drug efficacy and patient compliance, potentially transforming the landscape of pharmaceutical care.

KEY MARKET STATISTICS
Base Year [2023] USD 2.42 trillion
Estimated Year [2024] USD 2.55 trillion
Forecast Year [2030] USD 3.56 trillion
CAGR (%) 5.70%

Dosage Form: Convenience and effectiveness of oral formulations for chronic treatments

Inhalation formulations are designed for direct delivery to the respiratory tract. They are primarily used for conditions affecting the lungs, such as asthma and chronic obstructive pulmonary disease (COPD). This delivery method offers rapid onset of action and reduced systemic side effects. It is preferred for pulmonary conditions requiring fast relief or management. Oral formulations, including tablets, capsules, and liquids, are the most common form of drug administration. They are designed for systemic absorption through the gastrointestinal (GI) tract and were widely preferred for chronic diseases due to ease of administration and patient compliance. Parenteral formulations are administered bypassing the GI tract, mainly through intravenous, intramuscular, and subcutaneous routes. They are critical for treatments that require rapid absorption or when the drug is poorly absorbed from the gut. It is essential for emergency medicines, biologics, and treatments requiring precise control over drug bioavailability. Topical formulations include creams, ointments, gels, and patches applied to the skin's surface. They are primarily used for localized treatment, offering the advantage of minimizing systemic exposure. It is ideal for dermatological conditions and pain management through localized drug delivery.

End User: Rising investments in drug developments by pharmaceutical companies

Academic and research institutions primarily focus on developing innovative formulations and drug delivery systems. They often explore novel compounds with potential therapeutic benefits. Contract development & manufacturing organizations (CDMOs) are pivotal in the drug formulation sector, providing a wide range of services from drug development to manufacturing. They focus on flexibility, scalability, and speed-to-market, catering to pharmaceutical companies that aim to outsource these aspects to focus on their core competencies. Hospitals and clinics are the primary end users focusing on patient care through the administration of drugs. Their preference leans towards pharmaceuticals that are safe, effective, and offer better patient compliance. This sector is particularly interested in formulations that can simplify dosing regimes and enhance therapeutic outcomes. Pharmaceutical companies are central to the drug formulation industry, engaged in the discovery, development, production, and marketing of medications.

Regional Insights

In the Americas, especially the United States, there is a significant emphasis on innovative drug formulation technologies due to the presence of major pharmaceutical companies and a well-established regulatory framework led by the FDA. This promotes a high level of investment in research and development (R&D), focusing on complex formulations such as biologics and sustained-release drugs. The production capacity in the Americas is also bolstered by advanced manufacturing facilities, enabling rapid scalability of new formulations. APAC is rapidly emerging as a key player in the drug formulation market, driven by increasing healthcare expenditure, growing demand for generic medicines, and improvements in regulatory frameworks. Countries like India and China are leading in the production of generics, leveraging cost-effective manufacturing and a large pool of scientific talent. The EMEA region presents a mature market with a strong focus on high-quality drug formulations and stringent regulatory standards, especially in the European Union (EU) countries. Companies in the EMEA region are leading in advanced drug delivery systems and personalized medicine, supported by robust healthcare systems and significant government and private investment in pharmaceutical R&D.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Drug Formulation Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Drug Formulation Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Drug Formulation Market, highlighting leading vendors and their innovative profiles. These include 3M Company, AbbVie Inc., Amgen, Inc., AstraZeneca plc., Bayer AG, Boehringer Ingelheim International GmbH, Boston Scientific Corporation, Catalent, Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, Gerresheimer AG, Gilead Sciences, Inc., GlaxoSmithKline plc, Glenmark Pharmaceuticals Limited, Halozyme Therapeutics, Inc., Johnson & Johnson Services, Inc., Marksans Pharma Ltd., Medicef Pharma, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi SA, Teva Pharmaceuticals Industries Ltd., and The Bristol-Myers Squibb Company.

Market Segmentation & Coverage

This research report categorizes the Drug Formulation Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Dosage Form
    • Inhalation Formulations
      • Dry Powder Inhaler
      • Nebulizer
      • Pressurized Metered Dose Inhaler
    • Oral Formulations
      • Capsules
      • Gummies
      • Lozenges & Pastilles
      • Powders & Granules
      • Tablets
    • Parenteral Formulations
      • Emulsions
      • Gels
      • Powders
      • Solutions
      • Suspensions
    • Topical Formulations
      • Creams, Lotions, & Foams
      • Gels, Tinctures, & Powders
      • Ointments & Oils
      • Pastes
      • Sprays & Patches
  • Technology
    • Immediate-Release Formulations
    • Liposomal Formulations
    • Microsphere Formulations
    • Modified-Release Formulations
    • Nanoformulations
    • Self-Emulsifying Drug Delivery Systems
    • Solid Dispersion Formulations
  • Therapeutic Area
    • Cardiovascular
    • Central Nervous System
    • Dermatology
    • Endocrinology
    • Gastrointestinal
    • Immunology
    • Infectious Diseases
    • Oncology
    • Ophthalmology
    • Pain Management
    • Respiratory
  • End User
    • Academic & Research Institutions
    • Contract Development & Manufacturing Organizations
    • Hospitals & Clinics
    • Pharmaceutical Companies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Drug Formulation Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Drug Formulation Market?

3. What are the technology trends and regulatory frameworks in the Drug Formulation Market?

4. What is the market share of the leading vendors in the Drug Formulation Market?

5. Which modes and strategic moves are suitable for entering the Drug Formulation Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of chronic diseases and need for effective treatments
      • 5.1.1.2. Government initiatives encouraging drug development and discovery
      • 5.1.1.3. Rise of personalized and tailored medicine and therapies
    • 5.1.2. Restraints
      • 5.1.2.1. Adverse recalls of drugs and medications
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in drug delivery and dosage technologies
      • 5.1.3.2. Investments in CDMOs to develop generic drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Complex development and processing of drug formulations
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Dosage Form: Convenience and effectiveness of oral formulations for chronic treatments
    • 5.2.2. End User: Rising investments in drug developments by pharmaceutical companies
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Drug Formulation Market, by Dosage Form

  • 6.1. Introduction
  • 6.2. Inhalation Formulations
  • 6.3. Oral Formulations
  • 6.4. Parenteral Formulations
  • 6.5. Topical Formulations

7. Drug Formulation Market, by Technology

  • 7.1. Introduction
  • 7.2. Immediate-Release Formulations
  • 7.3. Liposomal Formulations
  • 7.4. Microsphere Formulations
  • 7.5. Modified-Release Formulations
  • 7.6. Nanoformulations
  • 7.7. Self-Emulsifying Drug Delivery Systems
  • 7.8. Solid Dispersion Formulations

8. Drug Formulation Market, by Therapeutic Area

  • 8.1. Introduction
  • 8.2. Cardiovascular
  • 8.3. Central Nervous System
  • 8.4. Dermatology
  • 8.5. Endocrinology
  • 8.6. Gastrointestinal
  • 8.7. Immunology
  • 8.8. Infectious Diseases
  • 8.9. Oncology
  • 8.10. Ophthalmology
  • 8.11. Pain Management
  • 8.12. Respiratory

9. Drug Formulation Market, by End User

  • 9.1. Introduction
  • 9.2. Academic & Research Institutions
  • 9.3. Contract Development & Manufacturing Organizations
  • 9.4. Hospitals & Clinics
  • 9.5. Pharmaceutical Companies

10. Americas Drug Formulation Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Drug Formulation Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Drug Formulation Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Glenmark Launches Triple Drug Formulation for Type 2 Diabetes Patients in India
    • 13.3.2. Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Application for INGREZZA (valbenazine) Oral Granules Sprinkle Formulation
    • 13.3.3. Merck & XtalPi Collaboration Optimizes Drug Formulations with AI-Powered Techniques
  • 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. DRUG FORMULATION MARKET RESEARCH PROCESS
  • FIGURE 2. DRUG FORMULATION MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DRUG FORMULATION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DRUG FORMULATION MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL DRUG FORMULATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. DRUG FORMULATION MARKET DYNAMICS
  • FIGURE 7. GLOBAL DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL DRUG FORMULATION MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL DRUG FORMULATION MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES DRUG FORMULATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES DRUG FORMULATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. DRUG FORMULATION MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. DRUG FORMULATION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DRUG FORMULATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DRUG FORMULATION MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL DRUG FORMULATION MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL DRUG FORMULATION MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL DRUG FORMULATION MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL DRUG FORMULATION MARKET SIZE, BY DRY POWDER INHALER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL DRUG FORMULATION MARKET SIZE, BY DRY POWDER INHALER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL DRUG FORMULATION MARKET SIZE, BY NEBULIZER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL DRUG FORMULATION MARKET SIZE, BY NEBULIZER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL DRUG FORMULATION MARKET SIZE, BY PRESSURIZED METERED DOSE INHALER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL DRUG FORMULATION MARKET SIZE, BY PRESSURIZED METERED DOSE INHALER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL DRUG FORMULATION MARKET SIZE, BY CAPSULES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL DRUG FORMULATION MARKET SIZE, BY CAPSULES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL DRUG FORMULATION MARKET SIZE, BY GUMMIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL DRUG FORMULATION MARKET SIZE, BY GUMMIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL DRUG FORMULATION MARKET SIZE, BY LOZENGES & PASTILLES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL DRUG FORMULATION MARKET SIZE, BY LOZENGES & PASTILLES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL DRUG FORMULATION MARKET SIZE, BY POWDERS & GRANULES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL DRUG FORMULATION MARKET SIZE, BY POWDERS & GRANULES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL DRUG FORMULATION MARKET SIZE, BY TABLETS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL DRUG FORMULATION MARKET SIZE, BY TABLETS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL DRUG FORMULATION MARKET SIZE, BY EMULSIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL DRUG FORMULATION MARKET SIZE, BY EMULSIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL DRUG FORMULATION MARKET SIZE, BY GELS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL DRUG FORMULATION MARKET SIZE, BY GELS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL DRUG FORMULATION MARKET SIZE, BY POWDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL DRUG FORMULATION MARKET SIZE, BY POWDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL DRUG FORMULATION MARKET SIZE, BY SOLUTIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL DRUG FORMULATION MARKET SIZE, BY SOLUTIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL DRUG FORMULATION MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL DRUG FORMULATION MARKET SIZE, BY SUSPENSIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL DRUG FORMULATION MARKET SIZE, BY CREAMS, LOTIONS, & FOAMS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL DRUG FORMULATION MARKET SIZE, BY CREAMS, LOTIONS, & FOAMS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL DRUG FORMULATION MARKET SIZE, BY GELS, TINCTURES, & POWDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL DRUG FORMULATION MARKET SIZE, BY GELS, TINCTURES, & POWDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL DRUG FORMULATION MARKET SIZE, BY OINTMENTS & OILS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL DRUG FORMULATION MARKET SIZE, BY OINTMENTS & OILS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL DRUG FORMULATION MARKET SIZE, BY PASTES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL DRUG FORMULATION MARKET SIZE, BY PASTES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL DRUG FORMULATION MARKET SIZE, BY SPRAYS & PATCHES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL DRUG FORMULATION MARKET SIZE, BY SPRAYS & PATCHES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 61. GLOBAL DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 62. GLOBAL DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 63. GLOBAL DRUG FORMULATION MARKET SIZE, BY IMMEDIATE-RELEASE FORMULATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 64. GLOBAL DRUG FORMULATION MARKET SIZE, BY IMMEDIATE-RELEASE FORMULATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 65. GLOBAL DRUG FORMULATION MARKET SIZE, BY LIPOSOMAL FORMULATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 66. GLOBAL DRUG FORMULATION MARKET SIZE, BY LIPOSOMAL FORMULATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 67. GLOBAL DRUG FORMULATION MARKET SIZE, BY MICROSPHERE FORMULATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 68. GLOBAL DRUG FORMULATION MARKET SIZE, BY MICROSPHERE FORMULATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 69. GLOBAL DRUG FORMULATION MARKET SIZE, BY MODIFIED-RELEASE FORMULATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 70. GLOBAL DRUG FORMULATION MARKET SIZE, BY MODIFIED-RELEASE FORMULATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 71. GLOBAL DRUG FORMULATION MARKET SIZE, BY NANOFORMULATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 72. GLOBAL DRUG FORMULATION MARKET SIZE, BY NANOFORMULATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 73. GLOBAL DRUG FORMULATION MARKET SIZE, BY SELF-EMULSIFYING DRUG DELIVERY SYSTEMS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 74. GLOBAL DRUG FORMULATION MARKET SIZE, BY SELF-EMULSIFYING DRUG DELIVERY SYSTEMS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 75. GLOBAL DRUG FORMULATION MARKET SIZE, BY SOLID DISPERSION FORMULATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 76. GLOBAL DRUG FORMULATION MARKET SIZE, BY SOLID DISPERSION FORMULATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 77. GLOBAL DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 78. GLOBAL DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 79. GLOBAL DRUG FORMULATION MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 80. GLOBAL DRUG FORMULATION MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 81. GLOBAL DRUG FORMULATION MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 82. GLOBAL DRUG FORMULATION MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 83. GLOBAL DRUG FORMULATION MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 84. GLOBAL DRUG FORMULATION MARKET SIZE, BY DERMATOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 85. GLOBAL DRUG FORMULATION MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 86. GLOBAL DRUG FORMULATION MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 87. GLOBAL DRUG FORMULATION MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 88. GLOBAL DRUG FORMULATION MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 89. GLOBAL DRUG FORMULATION MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 90. GLOBAL DRUG FORMULATION MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 91. GLOBAL DRUG FORMULATION MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 92. GLOBAL DRUG FORMULATION MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 93. GLOBAL DRUG FORMULATION MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 94. GLOBAL DRUG FORMULATION MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 95. GLOBAL DRUG FORMULATION MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 96. GLOBAL DRUG FORMULATION MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 97. GLOBAL DRUG FORMULATION MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 98. GLOBAL DRUG FORMULATION MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 99. GLOBAL DRUG FORMULATION MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 100. GLOBAL DRUG FORMULATION MARKET SIZE, BY RESPIRATORY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 101. GLOBAL DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 102. GLOBAL DRUG FORMULATION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 103. GLOBAL DRUG FORMULATION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 104. GLOBAL DRUG FORMULATION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 105. GLOBAL DRUG FORMULATION MARKET SIZE, BY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 106. GLOBAL DRUG FORMULATION MARKET SIZE, BY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 107. GLOBAL DRUG FORMULATION MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 108. GLOBAL DRUG FORMULATION MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 109. GLOBAL DRUG FORMULATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 110. GLOBAL DRUG FORMULATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 111. AMERICAS DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 112. AMERICAS DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 113. AMERICAS DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 114. AMERICAS DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 115. AMERICAS DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 116. AMERICAS DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 117. AMERICAS DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 118. AMERICAS DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 119. AMERICAS DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 120. AMERICAS DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 121. AMERICAS DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 122. AMERICAS DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 123. AMERICAS DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 124. AMERICAS DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 125. AMERICAS DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 126. AMERICAS DRUG FORMULATION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 127. AMERICAS DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 128. AMERICAS DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 129. ARGENTINA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 130. ARGENTINA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 131. ARGENTINA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 132. ARGENTINA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 133. ARGENTINA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 134. ARGENTINA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 135. ARGENTINA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 136. ARGENTINA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 137. ARGENTINA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 138. ARGENTINA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 139. ARGENTINA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 140. ARGENTINA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 141. ARGENTINA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 142. ARGENTINA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 143. ARGENTINA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 144. ARGENTINA DRUG FORMULATION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 145. BRAZIL DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 146. BRAZIL DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 147. BRAZIL DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 148. BRAZIL DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 149. BRAZIL DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 150. BRAZIL DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 151. BRAZIL DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 152. BRAZIL DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 153. BRAZIL DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 154. BRAZIL DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 155. BRAZIL DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 156. BRAZIL DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 157. BRAZIL DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 158. BRAZIL DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 159. BRAZIL DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 160. BRAZIL DRUG FORMULATION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 161. CANADA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 162. CANADA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 163. CANADA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 164. CANADA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 165. CANADA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 166. CANADA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 167. CANADA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 168. CANADA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 169. CANADA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 170. CANADA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 171. CANADA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 172. CANADA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 173. CANADA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 174. CANADA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 175. CANADA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 176. CANADA DRUG FORMULATION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 177. MEXICO DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 178. MEXICO DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 179. MEXICO DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 180. MEXICO DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 181. MEXICO DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 182. MEXICO DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 183. MEXICO DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 184. MEXICO DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 185. MEXICO DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 186. MEXICO DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 187. MEXICO DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 188. MEXICO DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 189. MEXICO DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 190. MEXICO DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 191. MEXICO DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 192. MEXICO DRUG FORMULATION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 193. UNITED STATES DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 194. UNITED STATES DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 195. UNITED STATES DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 196. UNITED STATES DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 197. UNITED STATES DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 198. UNITED STATES DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 199. UNITED STATES DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 200. UNITED STATES DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 201. UNITED STATES DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 202. UNITED STATES DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 203. UNITED STATES DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 204. UNITED STATES DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 205. UNITED STATES DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 206. UNITED STATES DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 207. UNITED STATES DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 208. UNITED STATES DRUG FORMULATION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 209. UNITED STATES DRUG FORMULATION MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 210. UNITED STATES DRUG FORMULATION MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 229. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 230. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 231. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 232. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 233. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 234. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 235. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 236. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 237. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 238. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 239. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 240. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 241. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 242. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 243. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 244. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 245. CHINA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 246. CHINA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 247. CHINA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 248. CHINA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 249. CHINA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 250. CHINA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 251. CHINA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 252. CHINA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 253. CHINA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 254. CHINA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 255. CHINA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 256. CHINA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 257. CHINA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 258. CHINA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 259. CHINA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 260. CHINA DRUG FORMULATION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 261. INDIA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 262. INDIA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 263. INDIA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 264. INDIA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 265. INDIA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 266. INDIA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 267. INDIA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 268. INDIA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 269. INDIA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 270. INDIA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 271. INDIA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 272. INDIA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 273. INDIA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 274. INDIA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 275. INDIA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 276. INDIA DRUG FORMULATION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 277. INDONESIA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 278. INDONESIA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 279. INDONESIA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 280. INDONESIA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 281. INDONESIA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 282. INDONESIA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 283. INDONESIA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 284. INDONESIA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 285. INDONESIA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 286. INDONESIA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 287. INDONESIA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 288. INDONESIA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 289. INDONESIA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 290. INDONESIA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 291. INDONESIA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 292. INDONESIA DRUG FORMULATION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 293. JAPAN DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 294. JAPAN DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 295. JAPAN DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 296. JAPAN DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 297. JAPAN DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 298. JAPAN DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 299. JAPAN DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 300. JAPAN DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 301. JAPAN DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 302. JAPAN DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 303. JAPAN DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 304. JAPAN DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 305. JAPAN DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 306. JAPAN DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 307. JAPAN DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 308. JAPAN DRUG FORMULATION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 309. MALAYSIA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 310. MALAYSIA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 311. MALAYSIA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 312. MALAYSIA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 313. MALAYSIA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 314. MALAYSIA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 315. MALAYSIA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 316. MALAYSIA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 317. MALAYSIA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 318. MALAYSIA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 319. MALAYSIA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 320. MALAYSIA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 321. MALAYSIA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 322. MALAYSIA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 323. MALAYSIA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 324. MALAYSIA DRUG FORMULATION MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 325. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 326. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 327. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 328. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 329. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 330. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 331. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 332. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 333. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2023 (USD MILLION)
  • TABLE 334. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2024-2030 (USD MILLION)
  • TABLE 335. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 336. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 337. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 338. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILL